From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Cell Type
“TIL average” method, r2
“Immune hotspot” method, r2
CD3+
0.67
0.04
CD8+
0.63
0.06
PD-L1+
.042
0.34
PD-L1+ CD3+
0.74
0.29
CD163+
0.61
0.43